WallStreetZenWallStreetZen

NASDAQ: HARP
Harpoon Therapeutics Inc Stock Ownership - Who owns Harpoon Therapeutics?

Insider buying vs selling

Have Harpoon Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Ronald HuntDirector2023-03-2310,000$1.00k
$10.00MBuy

1 of 1

HARP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HARP insiders and whales buy or sell their stock.

HARP Shareholders

What type of owners hold Harpoon Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Ansbert Gadicke16.83%6,328,095$4.87MInsider
Luke Evnin12.03%4,524,425$3.48MInsider
Ubs Oncology Impact Fund LP10.37%3,898,422$3.00MInsider
Mpm Bioventures 2014 LP8.57%3,220,844$2.48MInsider
Bioimpact Capital LLC8.50%3,196,707$2.46MInstitution
New Leaf Venture Partners LLC8.40%3,156,699$2.43MInstitution
New Leaf Biopharma Opportunities Ii LP8.40%3,156,699$2.43MInsider
Mpm Asset Management LLC8.33%3,131,388$2.41MInstitution
Mark Chin6.89%2,590,644$1.99MInsider
New Leaf Ventures Iii LP5.97%2,242,839$1.73MInsider

1 of 3

HARP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HARP37.57%62.43%Net BuyingNet Buying
KA0.99%99.01%Net BuyingNet Selling
UNCY11.07%0.74%
MTEM13.47%86.53%Net Buying
RGLS4.31%95.69%Net BuyingNet Buying

Harpoon Therapeutics Stock Ownership FAQ

Who owns Harpoon Therapeutics?

Harpoon Therapeutics (NASDAQ: HARP) is owned by 46.29% institutional shareholders, 76.93% Harpoon Therapeutics insiders, and 0.00% retail investors. Ansbert Gadicke is the largest individual Harpoon Therapeutics shareholder, owning 6.33M shares representing 16.83% of the company. Ansbert Gadicke's Harpoon Therapeutics shares are currently valued at $4.63M.

If you're new to stock investing, here's how to buy Harpoon Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.